Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 134, P. 102902 - 102902
Published: Feb. 16, 2025
Language: Английский
Breast Cancer, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 29, 2025
Language: Английский
Citations
1
Nature Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: April 10, 2025
Language: Английский
Citations
1
Drugs, Journal Year: 2025, Volume and Issue: unknown
Published: May 5, 2025
Language: Английский
Citations
1
Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 652 - 652
Published: May 17, 2024
Precise targeting has become the main direction of anti-cancer drug development. Trophoblast cell surface antigen 2 (Trop-2) is highly expressed in different solid tumors but rarely normal tissues, rendering it an attractive target. Trop-2-targeted antibody-drug conjugates (ADCs) have displayed promising efficacy treating diverse tumors, especially breast cancer and urothelial carcinoma. However, their clinical application still limited by insufficient efficacy, excessive toxicity, lack biological markers related to effectiveness. This review summarizes trials combination therapy strategies for ADCs, discusses current challenges, provides new insights future advancements.
Language: Английский
Citations
8
MedComm, Journal Year: 2024, Volume and Issue: 5(8)
Published: July 28, 2024
Abstract Antibody–drug conjugates (ADCs) consist of monoclonal antibodies that target tumor cells and cytotoxic drugs linked through linkers. By leveraging antibodies’ targeting properties, ADCs deliver into via endocytosis after identifying the antigen. This precise method aims to kill selectively while minimizing harm normal cells, offering safe effective therapeutic benefits. Recent years have seen significant progress in antitumor treatment with ADC development, providing patients new potent options. With over 300 explored for various indications some already approved clinical use, challenges such as resistance due factors like antigen expression, processing, payload emerged. review outline history their structure, mechanism action, recent composition advancements, selection, completed ongoing trials, mechanisms, intervention strategies. Additionally, it will delve potential novel markers, linkers, payloads, innovative action mechanisms enhance cancer The evolution has also led emergence combination therapy a approach improve drug efficacy.
Language: Английский
Citations
7
Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(9), P. 1146 - 1146
Published: Aug. 29, 2024
The advent of immunotherapy and antibody–drug conjugates (ADCs) have revolutionized breast cancer treatment, offering new hope to patients. However, challenges, such as resistance limited efficacy in certain cases, remain. Recently, the combination these therapies has emerged a promising approach address challenges. ADCs play crucial role by delivering cytotoxic agents directly cells, minimizing damage healthy tissue enhancing tumor-killing effect. Concurrently, immunotherapies harness body’s immune system recognize eliminate cells. This integration offers potential overcome mechanisms significantly improve therapeutic outcomes. review explores rationale behind combining with ADCs, recent advances this field, implications for treatment.
Language: Английский
Citations
7
Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(6), P. 727 - 742
Published: April 12, 2024
The introduction of targeted therapy and immunotherapy has tremendously changed the clinical outcomes prognosis cancer patients. Despite innovative pharmacological therapies improved radiotherapy (RT) techniques, patients continue to suffer from side effects, which oral mucositis (OM) is still most impactful, especially for quality life. We provide an overview current advances in pharmacotherapy RT, relation their potential cause OM, less explored more recent literature reports related best management OM. have analyzed natural/antioxidant agents, probiotics, mucosal protectants healing coadjuvants, pharmacotherapies, immunomodulatory anticancer photobiomodulation impact technology. discovery precise pathophysiologic mechanisms CT RT-induced OM outlined that a multifactorial origin, including direct oxidative damage, upregulation immunologic factors, effects on flora. A persistent upregulated immune response, associated with factors patients' characteristics, may contribute severe long-lasting goal strategies conjugate individual patient, disease, therapy-related guide prevention or treatment. further high-quality research warranted, issue paramount future strategies.
Language: Английский
Citations
5
BJU International, Journal Year: 2024, Volume and Issue: 134(4), P. 615 - 621
Published: June 19, 2024
Objective To evaluate the potential utility of antibody‐drug conjugates targeting trophoblast cell surface antigen‐2 (TROP‐2) in patients with primary penile squamous carcinoma (PSCC), recurrence (REC cohort), and patient‐matched distant metastases (MET to assess use TROP‐2 as a predictive non‐invasive biomarker PSCC. Methods A cohort comprising PRIM ( n = 37), REC 5) MET subcohort 7), including lymph node lung metastases, was analysed using quantitative real‐time PCR, ELISA immunohistochemical staining evaluation H‐score. Results mRNA serum protein levels were significantly increased recurrent PSCC compared cancer‐free controls (both P < 0.001). Immunohistochemical analysis revealed that most 34/37, median H‐score 260, interquartile range [IQR] 210–300), well all (median 200 [165–290]) cohorts 280 [260–300]) exhibited moderate strong membranous expression. Additionally, The (membranous expression) positively correlated ρ 0.69, 0.0001, R 2 0.70) 0.86, 0.59), indicating its Conclusion In summary, our results support further studies on diagnostic therapeutic target primary, metastatic
Language: Английский
Citations
5
International Journal of Gynecological Cancer, Journal Year: 2024, Volume and Issue: 34(11), P. 1795 - 1804
Published: July 29, 2024
Clinical outcomes remain challenging in advanced or recurrent endometrial cancer due to tumor heterogeneity and therapy resistance. Antibody-drug conjugates are a novel class of therapeutics, representing promising treatment option for cancer. consist high-affinity antibody linked cytotoxic payload through stable linker. After binding specific antigens on cells, the drug is internalized, released. In addition, free intracellular may be released outside target cell 'bystander effect' kill neighboring which crucial treating malignancies characterized by heterogeneous biomarker expression like This article aims provide comprehensive overview current clinical landscape antibody-drug We conducted thorough analysis recent trials focusing efficacy, safety profiles, mechanisms focused particularly most conjugate targets under investigation, such as human epidermal growth factor receptor 2 (HER2), folate alpha (FRα), trophoblast cell-surface antigen-2 (TROP2), B7-H4. also briefly comment challenges, including emergence resistance mechanisms, future development directions (especially agents targeting multiple antigens, combinatorial strategies, sequential use same antigen but using different payloads)
Language: Английский
Citations
5
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Jan. 4, 2024
Abstract Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences decision-making between treatment active surveillance. The development of novel predictive biomarkers will help with risk stratification, decision-making, leading to decrease in over or under-treatment patients cancer. Here, we report that Trop2 prognostic tissue biomarker for by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed 1100 multi-institutional study. We demonstrate elevated expression correlated worse features including Gleason score, age, pre-operative PSA levels. More importantly, at radical prostatectomy predicts overall survival men undergoing prostatectomy. Additionally, detect shed urine Our study identifies as candidate non-invasive marker
Language: Английский
Citations
4